Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients.

"Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: M. K. W. received research funding from the Patient-Centered Outcomes Research Institute and the Office of the Assistant Secretary for Preparedness and Response; and is an unpaid advisor to National Academies of Sciences, Engineering, and Medicine, including on crisis standards of care during the COVID-19 pandemic, and to the Defense Advanced Research Projects Agency, the Hastings Center, and the Lancet on projects unrelated to mAb treatment. T. D. B. and N. E. C. have received research grants from the National Institutes of Health outside the current work. A. A. G. has received other COVID-19 research grants from the National Institutes of Health, Department of Defense, Centers for Disease Control and Prevention, AbbVie, and Faron Pharmaceuticals, outside the current work. None declared (L. E. B., C. B. D., B. M. K., D. A. M., T. C. O., S. R., J. D. S., H. R. S., A. F. W., R. D. Z., R. J. S.)."

"Funding/Support This study was funded by 10.13039/100000002National Institutes of Health/10.13039/100006108National Center for Advancing Translational Sciences [grants UL1TR002525, UL1TR002535-03S3, and UL1TR002535-04S2]."